EP3497231C0 - Bakterielle systeme zur analyse von ubiquitinierten polypeptiden - Google Patents

Bakterielle systeme zur analyse von ubiquitinierten polypeptiden

Info

Publication number
EP3497231C0
EP3497231C0 EP17838924.3A EP17838924A EP3497231C0 EP 3497231 C0 EP3497231 C0 EP 3497231C0 EP 17838924 A EP17838924 A EP 17838924A EP 3497231 C0 EP3497231 C0 EP 3497231C0
Authority
EP
European Patent Office
Prior art keywords
analyzing
bacterial systems
ubiquitinated polypeptides
ubiquitinated
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP17838924.3A
Other languages
English (en)
French (fr)
Other versions
EP3497231A4 (de
EP3497231A1 (de
EP3497231B1 (de
Inventor
Gali Prag
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technology Innovation Momentum Fund Israel LP
Original Assignee
Technology Innovation Momentum Fund Israel LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technology Innovation Momentum Fund Israel LP filed Critical Technology Innovation Momentum Fund Israel LP
Publication of EP3497231A1 publication Critical patent/EP3497231A1/de
Publication of EP3497231A4 publication Critical patent/EP3497231A4/de
Application granted granted Critical
Publication of EP3497231C0 publication Critical patent/EP3497231C0/de
Publication of EP3497231B1 publication Critical patent/EP3497231B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1025Acyltransferases (2.3)
    • C12N9/104Aminoacyltransferases (2.3.2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/95Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/9015Ligases (6)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/91045Acyltransferases (2.3)
    • G01N2333/91074Aminoacyltransferases (general) (2.3.2)
    • G01N2333/9108Aminoacyltransferases (general) (2.3.2) with definite EC number (2.3.2.-)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/02Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP17838924.3A 2016-08-08 2017-08-08 Bakterielle systeme zur analyse von ubiquitinierten polypeptiden Active EP3497231B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662371881P 2016-08-08 2016-08-08
PCT/IL2017/050876 WO2018029682A1 (en) 2016-08-08 2017-08-08 Bacterial systems for analyzing ubiquitylated polypeptides

Publications (4)

Publication Number Publication Date
EP3497231A1 EP3497231A1 (de) 2019-06-19
EP3497231A4 EP3497231A4 (de) 2020-04-15
EP3497231C0 true EP3497231C0 (de) 2023-10-04
EP3497231B1 EP3497231B1 (de) 2023-10-04

Family

ID=61161878

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17838924.3A Active EP3497231B1 (de) 2016-08-08 2017-08-08 Bakterielle systeme zur analyse von ubiquitinierten polypeptiden

Country Status (4)

Country Link
US (3) US10982252B2 (de)
EP (1) EP3497231B1 (de)
ES (1) ES2965761T3 (de)
WO (1) WO2018029682A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2965761T3 (es) 2016-08-08 2024-04-16 Tech Innovation Momentum Fund Israel Limited Partnership Sistemas bacterianos para el análisis de polipéptidos ubiquitilados
US11932846B2 (en) 2017-08-08 2024-03-19 Technology Innovation Momentum Fund (Israel) Limited Partnership Chloramphenicol resistant split protein and uses thereof
EP3867395A4 (de) * 2018-10-16 2022-07-20 Technology Innovation Momentum Fund (Israel) Limited Partnership Systeme und verfahren zum screenen von kleinen molekülen von interesse
CN112301131B (zh) * 2020-11-13 2021-10-26 中国医学科学院基础医学研究所 Rnf138作为预测结直肠癌对sc75741治疗敏感性的生物标志物的应用
CN112575003B (zh) * 2020-12-17 2022-02-15 中国农业科学院植物保护研究所 本氏烟hakai基因在调控植物抗病毒中的应用及转基因植物培育方法
IL279559A (en) 2020-12-17 2022-07-01 Yeda Res & Dev Controlling ubiquitination of mlkl for treatment of disease
CN116287218A (zh) * 2023-04-14 2023-06-23 湖北省妇幼保健院(湖北省妇女儿童医院) 一种ube3b突变基因、检测试剂盒、方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
DE10211063A1 (de) 2002-03-13 2003-10-09 Axaron Bioscience Ag Neue Verfahren zur Detektion und Analyse von Protein-Interaktionen in vivo
US20040043386A1 (en) 2002-08-30 2004-03-04 Todd Pray Methods and compositions for functional ubiquitin assays
WO2006044747A2 (en) 2004-10-15 2006-04-27 Signal Pharmaceuticals, Llc P27 ubiquitination assay and methods of use
US7588907B2 (en) 2005-06-02 2009-09-15 The Regents Of The University Of Michigan Ubiquitin mediated fluorescence complementation assay
US9388406B2 (en) 2008-11-17 2016-07-12 Cornell University System useful for reporting protein-protein interactions in the bacterial periplasm
ES2965761T3 (es) 2016-08-08 2024-04-16 Tech Innovation Momentum Fund Israel Limited Partnership Sistemas bacterianos para el análisis de polipéptidos ubiquitilados
US11932846B2 (en) 2017-08-08 2024-03-19 Technology Innovation Momentum Fund (Israel) Limited Partnership Chloramphenicol resistant split protein and uses thereof
EP3867395A4 (de) 2018-10-16 2022-07-20 Technology Innovation Momentum Fund (Israel) Limited Partnership Systeme und verfahren zum screenen von kleinen molekülen von interesse

Also Published As

Publication number Publication date
US20190185902A1 (en) 2019-06-20
WO2018029682A1 (en) 2018-02-15
EP3497231A4 (de) 2020-04-15
US20210269845A1 (en) 2021-09-02
ES2965761T3 (es) 2024-04-16
EP3497231A1 (de) 2019-06-19
US20250019737A1 (en) 2025-01-16
EP3497231B1 (de) 2023-10-04
US10982252B2 (en) 2021-04-20

Similar Documents

Publication Publication Date Title
EP3698872A4 (de) Mikrofluidischer detektions-chip zur mehrkanal-schnelldetektion
EP3428031C0 (de) Fahrerunterstütztes design-analysesystem
DK3548652T3 (da) Fremgangsmåder til proteinanalyse
EP3486584A4 (de) Kühlsystem
EP3497231C0 (de) Bakterielle systeme zur analyse von ubiquitinierten polypeptiden
EP4235690C0 (de) Systeme zur hautanalyse mit elektronischen vorrichtungen
MA42847A (fr) Analyse de micro-moment
EP3485235C0 (de) Systeme und verfahren zur kanalüberwachung
EP3521715A4 (de) Belüftungssystem
EP3286359C0 (de) Verfahren und systeme zur mehrfachen taxonomischen klassifizierung
EP3278248C0 (de) System zur digitalen identifizierung
EP3509494C0 (de) Systeme zur erkennung von iv-infiltration
EP3705236A4 (de) Robotersystem
EP3685735C0 (de) Vorrichtung zur vorhersage von thyreotoxikose
EP3665344A4 (de) Ausgabesystem
EP3638417A4 (de) Beschichtungssystem
EP3573757A4 (de) Systeme und verfahren zur ganzzelligen analyse
EP3702925A4 (de) Konferenzsystem
EP3347546A4 (de) Verkleidungssystem
EP3622085A4 (de) Systeme und methoden zur identifizierung und unterscheidung genetischer proben
SG11202103186SA (en) Analysis system
EP3867765A4 (de) Geführte sicherheitsanalyse für cyber-physische systeme
EP3664441A4 (de) Überwachungssystem
EP3716832A4 (de) Ausgabesystem
EP3441887A4 (de) Übersetzungssystem

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190311

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C12Q0001040000

Ipc: C12Q0001480000

Ref country code: DE

Ref legal event code: R079

Ref document number: 602017074991

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: C12Q0001040000

Ipc: C12Q0001480000

A4 Supplementary search report drawn up and despatched

Effective date: 20200317

RIC1 Information provided on ipc code assigned before grant

Ipc: C12Q 1/48 20060101AFI20200311BHEP

Ipc: C12N 9/10 20060101ALI20200311BHEP

Ipc: C12Q 1/02 20060101ALI20200311BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40011327

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220303

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20230412

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602017074991

Country of ref document: DE

U01 Request for unitary effect filed

Effective date: 20231102

U07 Unitary effect registered

Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI

Effective date: 20231108

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240105

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240204

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2965761

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20240416

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240204

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240105

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231004

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231004

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240104

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231004

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602017074991

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231004

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231004

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231004

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231004

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231004

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231004

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20240705

U20 Renewal fee for the european patent with unitary effect paid

Year of fee payment: 8

Effective date: 20240816

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231004

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240808

U20 Renewal fee for the european patent with unitary effect paid

Year of fee payment: 9

Effective date: 20250828

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20250918

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20250825

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20250901

Year of fee payment: 9